Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 20 studies | 47% ± 17% | |
peripheral blood | 18 studies | 48% ± 11% | |
brain | 18 studies | 32% ± 15% | |
intestine | 12 studies | 43% ± 20% | |
kidney | 9 studies | 46% ± 13% | |
eye | 9 studies | 43% ± 15% | |
bone marrow | 6 studies | 32% ± 14% | |
lymph node | 6 studies | 53% ± 20% | |
liver | 6 studies | 49% ± 23% | |
pancreas | 5 studies | 57% ± 25% | |
heart | 5 studies | 21% ± 9% | |
uterus | 5 studies | 56% ± 19% | |
adipose | 5 studies | 22% ± 8% | |
breast | 4 studies | 54% ± 5% | |
prostate | 4 studies | 55% ± 21% | |
placenta | 3 studies | 74% ± 5% | |
adrenal gland | 3 studies | 44% ± 17% | |
esophagus | 3 studies | 51% ± 28% | |
skin | 3 studies | 39% ± 16% | |
thymus | 3 studies | 63% ± 26% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 11595.69 | 1445 / 1445 | 100% | 293.43 | 183 / 183 |
ovary | 100% | 18860.42 | 180 / 180 | 100% | 282.57 | 430 / 430 |
stomach | 100% | 8499.94 | 359 / 359 | 100% | 311.93 | 286 / 286 |
uterus | 100% | 15502.41 | 170 / 170 | 100% | 362.48 | 458 / 459 |
lung | 100% | 13141.31 | 577 / 578 | 100% | 330.62 | 1154 / 1155 |
brain | 100% | 11063.22 | 2638 / 2642 | 100% | 289.86 | 704 / 705 |
intestine | 100% | 13085.56 | 966 / 966 | 100% | 356.75 | 525 / 527 |
liver | 100% | 8508.72 | 226 / 226 | 100% | 215.04 | 404 / 406 |
bladder | 100% | 14416.76 | 21 / 21 | 99% | 327.89 | 501 / 504 |
thymus | 100% | 12237.57 | 653 / 653 | 99% | 271.56 | 601 / 605 |
breast | 100% | 12636.12 | 459 / 459 | 99% | 366.97 | 1110 / 1118 |
prostate | 100% | 11221.48 | 245 / 245 | 99% | 278.67 | 498 / 502 |
pancreas | 99% | 6347.84 | 326 / 328 | 99% | 246.46 | 177 / 178 |
kidney | 100% | 12534.63 | 89 / 89 | 99% | 225.10 | 889 / 901 |
skin | 100% | 12535.19 | 1808 / 1809 | 98% | 242.08 | 463 / 472 |
adrenal gland | 100% | 10708.21 | 258 / 258 | 97% | 221.90 | 223 / 230 |
adipose | 100% | 12422.98 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 14428.83 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 291.72 | 29 / 29 |
muscle | 100% | 10774.39 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 10765.76 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 333.72 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 124.24 | 1 / 1 |
heart | 97% | 7359.72 | 837 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 10862.49 | 892 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 159.04 | 75 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042327 | Biological process | positive regulation of phosphorylation |
GO_0019371 | Biological process | cyclooxygenase pathway |
GO_0005978 | Biological process | glycogen biosynthetic process |
GO_0007165 | Biological process | signal transduction |
GO_0060430 | Biological process | lung saccule development |
GO_0051131 | Biological process | chaperone-mediated protein complex assembly |
GO_0042921 | Biological process | nuclear receptor-mediated glucocorticoid signaling pathway |
GO_0006457 | Biological process | protein folding |
GO_1905323 | Biological process | telomerase holoenzyme complex assembly |
GO_0050821 | Biological process | protein stabilization |
GO_0048144 | Biological process | fibroblast proliferation |
GO_0001516 | Biological process | prostaglandin biosynthetic process |
GO_0051973 | Biological process | positive regulation of telomerase activity |
GO_0000723 | Biological process | telomere maintenance |
GO_0051085 | Biological process | chaperone cofactor-dependent protein refolding |
GO_0043588 | Biological process | skin development |
GO_0007004 | Biological process | telomere maintenance via telomerase |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005697 | Cellular component | telomerase holoenzyme complex |
GO_0101031 | Cellular component | protein folding chaperone complex |
GO_0005829 | Cellular component | cytosol |
GO_0000781 | Cellular component | chromosome, telomeric region |
GO_0005634 | Cellular component | nucleus |
GO_0070182 | Molecular function | DNA polymerase binding |
GO_0051879 | Molecular function | Hsp90 protein binding |
GO_0051082 | Molecular function | unfolded protein binding |
GO_0051087 | Molecular function | protein-folding chaperone binding |
GO_0050220 | Molecular function | prostaglandin-E synthase activity |
GO_0003720 | Molecular function | telomerase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PTGES3 |
Protein name | Prostaglandin E synthase 3 (EC 5.3.99.3) (Cytosolic prostaglandin E2 synthase) (cPGES) (Hsp90 co-chaperone) (Progesterone receptor complex p23) (Telomerase-binding protein p23) Prostaglandin E synthase 3 (cPGES) (EC 5.3.99.3) (Cytosolic prostaglandin E2 synthase) Prostaglandin E synthase 3 |
Synonyms | TEBP hCG_2016483 P23 |
Description | FUNCTION: Cytosolic prostaglandin synthase that catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2) . Molecular chaperone that localizes to genomic response elements in a hormone-dependent manner and disrupts receptor-mediated transcriptional activation, by promoting disassembly of transcriptional regulatory complexes . Facilitates HIF alpha proteins hydroxylation via interaction with EGLN1/PHD2, leading to recruit EGLN1/PHD2 to the HSP90 pathway . . FUNCTION: Cytosolic prostaglandin synthase that catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2). Molecular chaperone that localizes to genomic response elements in a hormone-dependent manner and disrupts receptor-mediated transcriptional activation, by promoting disassembly of transcriptional regulatory complexes. Facilitates HIF alpha proteins hydroxylation. . FUNCTION: Cytosolic prostaglandin synthase that catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2). Molecular chaperone that localizes to genomic response elements in a hormone-dependent manner and disrupts receptor-mediated transcriptional activation, by promoting disassembly of transcriptional regulatory complexes. Facilitates HIF alpha proteins hydroxylation. . |
Accessions | B3KUY2 A0A087WYT3 ENST00000436399.6 [Q15185-2] ENST00000448157.6 [Q15185-4] B4DDC6 ENST00000456859.2 ENST00000614328.4 Q15185 ENST00000414274.7 [Q15185-3] ENST00000262033.11 [Q15185-1] |